Saxenda weekly recaps: what TikTok gets right and wrong about liraglutide

What did @thetravelingtwinmom actually say?

She reported losing "six whole pounds" in her first week on Saxenda (liraglutide), a GLP-1 receptor agonist she's using for weight loss and PCOS management. She mentioned nausea as a side effect, said she felt "really great" overall, and shared plans to increase her dose and start exercising. Short, honest, and reasonably specific, as week-one recaps go.

To her credit, she named the drug correctly, spelled out what it's for, and didn't make any wild efficacy promises. She framed it as a personal journey, not a medical recommendation. That matters on a platform where GLP-1 content can veer quickly into unqualified advice.

Does the science back this up?

The nausea report is textbook accurate. The six-pound week-one loss deserves more context than she gave it, and the PCOS claim, while plausible, is where things get complicated.

Liraglutide (Saxenda) is FDA-approved for chronic weight management in adults with a BMI of 30 or above, or 27 with at least one weight-related condition. The SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., 2015, New England Journal of Medicine) found participants lost an average of 8.4 kg over 56 weeks compared to 2.8 kg with placebo. That's meaningful, but it's a long-term average, not a week-one headline number.

On PCOS: liraglutide is not FDA-approved for PCOS, but the research is genuinely interesting. A randomized controlled trial by Jensterle et al. (2017, Journal of Clinical Endocrinology and Metabolism) found liraglutide improved menstrual regularity, reduced androgen levels, and aided weight loss in women with PCOS. So the use isn't fringe, but it is off-label, and that distinction is worth saying out loud.

Nausea affects roughly 39 percent of liraglutide users at the 3.0 mg dose according to the prescribing information, and is most common during dose escalation. She's at the start of that curve.

What did they get wrong (or right)?

The six-pound figure is where I'd pump the brakes. She presents it as a weight loss win, and emotionally it probably is. But early rapid loss on GLP-1 therapy is heavily influenced by water weight, reduced glycogen stores, and lower food volume, not just fat loss. Presenting it without that context could set unrealistic expectations for viewers who don't see the same number.

She got the nausea part right, and the framing matters: she said she had it but was "feeling really great" overall, which is a more honest representation than either minimizing the side effect or dramatizing it. That kind of calibrated personal reporting is actually useful to someone considering the drug.

The PCOS mention is accurate in the sense that liraglutide is being studied for PCOS, but she didn't say "off-label" or signal that this isn't a standard approved use. For a 94,000-view video, that gap could send people to their doctors asking for a PCOS treatment that their provider may not have flagged as investigational in this context.

She also didn't mention that dose escalation, which she says she's starting, is the phase when GI side effects typically worsen. Viewers preparing to increase their own dose deserve that heads-up.

What should you actually know?

If you're considering Saxenda, week one is almost never representative of your long-term results. Clinical trials measure outcomes over 52 to 68 weeks. Early numbers tend to be inflated by non-fat tissue changes, and they stabilize, sometimes plateau, before meaningful fat loss accumulates.

Liraglutide requires daily subcutaneous injection and a structured dose escalation schedule, typically starting at 0.6 mg and increasing weekly up to 3.0 mg. The purpose of going slow is GI tolerability. Skipping steps, or being encouraged by early results to rush, is a common reason people abandon the medication.

For PCOS specifically, if that's your primary reason for seeking a GLP-1, the evidence base is growing but still limited. The American Society for Reproductive Medicine does not currently include GLP-1 agonists in its standard PCOS treatment guidelines. That doesn't mean the drugs are unhelpful, but it does mean you need a clinician who is informed about the specific evidence, not just GLP-1s in general.

One more thing: combining a new injectable medication with starting a new workout routine in the same week, while also escalating dose, is a lot of physiological change at once. Nausea and exercise don't always mix well during dose escalation. That's not a reason to avoid either, but it's worth knowing before you commit to the gym the same week your dose goes up.